New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
The acquisition of Milan-based company will strengthen subsidiary Alivira Animal Health’s presence in Europe
The approval marks a major milestone in the global fight against antimicrobial resistance
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
We are building an AI-native operating system for pharma sales and distribution
Bengaluru startup targets 100+ enterprise clients and global expansion as it aims to transform pharmaceutical sales, marketing, tenders, and distribution using AI agents
Subscribe To Our Newsletter & Stay Updated
